This trial is testing a new way to deplete cancer cells in people with AML or MDS-EB.
5 Primary · 0 Secondary · Reporting Duration: 21 days
Experimental Treatment
55 Total Participants · 1 Treatment Group
Primary Treatment: MGTA-117 · No Placebo Group · Phase 1
Age 18 - 75 · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: